Accelr8 Announces Renewal and Expansion of SCHOTT Microarray License, and Notice of Allowance for New Patent
September 22 2011 - 8:00AM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced
that Accelr8 and SCHOTT Technical Glass Solutions, GmbH (Jena,
Germany) have renewed Accelr8’s license to SCHOTT for Nexterion®
microarraying slides using OptiChem® biocoatings. In addition to
renewing the existing non-exclusive license, Accelr8 also granted
to SCHOTT the right to sell OptiChem®-coated products for
application in medical diagnostics. Previously, SCHOTT’s license
excluded medical diagnostic applications. The new right for
diagnostic products allows SCHOTT to sell up to 20,000 units/year
to any single customer. If the customer plans to exceed this
volume, SCHOTT will refer the customer to Accelr8 to negotiate a
direct license from Accelr8.
In return for the license, SCHOTT paid $150,000 to Accelr8 for a
license fee and non-recourse pre-paid royalties. After reaching
cumulative sales that generate the prepaid royalty amount, SCHOTT
will pay additional cash royalties to Accelr8 for subsequent sales.
The term for the renewed license continues through November 24,
2014.
The new SCHOTT licensing rights join Accelr8’s previous direct
license to Nanosphere (NASDAQ: NSPH) in medical diagnostics.
Accelr8’s Web site includes OptiChem® information and links to
SCHOTT Nexterion’s® microarraying product Web
site—www.accelr8.com/pgen.php?pg=products_optichem.
Accelr8 also announced receipt of a Notice of Allowance from the
US Patent Office for broadened protection of methods used in
Accelr8’s BACcel™ culture-free, same-day pathogen diagnostic
system. Previously issued patents include system protection in the
US and international markets.
According to David Howson, Accelr8’s president, “we are pleased
with Schott’s decision to renew and expand its OptiChem® license in
microarraying products. We believe that Schott’s global marketing
reach can help capture new opportunities in the microarraying
market segment.”
“The new US patent expands our protection of fundamental methods
unique to our BACcel™ system. We believe that the new claims that
join our growing patent estate confer protection over basic
analytical principles, without limiting protection to a specific
narrow method of applying them. In our opinion, this issuance
significantly strengthens our intellectual property assets,” Howson
concluded.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection.
Accelr8 is developing a rapid analytical platform for infectious
pathogens, the BACcel™ system, based on its innovative surface
coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology
for use in applications outside of Accelr8’s own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Sep 2023 to Sep 2024